BCG Therapy Complications in Bladder Cancer
BCG therapy for bladder cancer causes local and systemic complications in approximately 70% of patients, with the most common being chemical cystitis (35%), flu-like symptoms (15%), and serious adverse events requiring treatment discontinuation in 8% of cases. 1
Local Complications
Chemical Cystitis and Lower Urinary Tract Symptoms
- Dysuria, frequency, and urgency occur in 60% of patients and represent the most frequent local side effects 2
- Chemical cystitis affects 35% of patients and is most severe in those with decreased bladder compliance before treatment 3
- Hematuria, bladder pain, and prostatitis are common across all intravesical treatments 4
- Symptom management with single-dose, short-term quinolones and/or anticholinergics reduces adverse events 2
Granulomatous Complications
- Bladder granulomas develop in approximately 30% of patients within the first 6 months after treatment 3
- These changes are temporary and do not correlate with long-term voiding symptoms 3
- Extravesical granulomas occur in 37% of patients and can cause urinary tract obstruction in 9% 3
- Late bladder contracture is rare when properly managed 3
Granulomatous Cystitis Management
- Immediately suspend BCG instillations when granulomatous cystitis develops 5, 6
- Initiate anti-tuberculosis therapy with isoniazid and rifampicin for 3 months, plus quinolones and corticosteroids 6
- Consider intravesical quinolone and anti-inflammatory instillations daily for 5 days if symptoms persist 6
Systemic Complications
Flu-like Symptoms
- Systemic symptoms resembling influenza occur in 31% of patients and typically last 48-72 hours 1, 2
- BCG induces a non-specific immunostimulatory response with pro-inflammatory cytokine secretion 2, 5
- The immune response activates neutrophils, monocytes, macrophages, T cells, and NK cells 2, 7
- Severe systemic symptoms occur in approximately 6% of patients 3
Serious Systemic Complications
- Potentially serious complications occur in 6% of patients, including sepsis and death 3, 8
- Hypersensitivity pneumonitis can develop from granulomatous inflammation in the lungs 5
- Patients with persistent flu-like symptoms beyond 72 hours require immediate evaluation for systemic BCG infection 5
Hypersensitivity Pneumonitis
- Immediately suspend BCG instillations when hypersensitivity pneumonitis is suspected 5
- Patients with prior BCG-induced hypersensitivity pneumonitis should never receive further BCG therapy 5
- Alternative intravesical agents must be considered for ongoing bladder cancer management 5
Risk Factors for Complications
Patient-Related Factors
- Decreased bladder capacity under anesthesia predicts severe cystitis 3
- Immunosuppression is a relative contraindication to BCG use 3
- BCG has cumulative effects, so increased toxicity occurs during long-term administration 3
Procedure-Related Factors
- Traumatic catheterization or instillation within 2 weeks of TURBT increases systemic absorption risk 5
- Pretreatment skin reactivity does not correlate with toxicity 3
Treatment Discontinuation
Frequency and Timing
- 8% of patients stop treatment due to side effects 1
- Among patients receiving 3-year BCG maintenance, 5.4% stop during the first year and 3.2% stop in years 2-3 1
- Side effects requiring treatment cessation occur most frequently in the first year 1
Management Strategies
- Reduce BCG dose (used in 17% of patients with toxicity) 3
- Temporarily interrupt treatment (5% of patients) 3
- Permanent cessation (4% of patients) 3
- One-third dose BCG has similar side effect profiles to full dose 1
BCG Intolerance Definition
- BCG-intolerant disease is defined as persistent disease due to inability to receive adequate BCG because of toxicity 9
- These patients require alternative management strategies including radical cystectomy or alternative intravesical agents 9
Critical Safety Considerations
Contraindications in Other Conditions
- BCG should never be offered for interstitial cystitis/bladder pain syndrome outside investigational settings due to lack of efficacy and serious adverse events including sepsis and death 8